The Latest Cardiac and Vascular News
BOSTON–(BUSINESS WIRE)–Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has named Dr. Robert “Bob” Pelberg as its new senior vice president of medical affairs. A highly accomplished cardiologist and nationally recognized expert in cardiovascular computed tomography […]
1.3 million patients are hospitalized annually in the U.S. from acute heart failure and it is the #1 cause of hospitalization in patients >65 years old
– Company engages U.S. critical care professionals with data-driven early warning solution MARLBOROUGH, Mass., May 26, 2025 /PRNewswire/ — VUNO, a global medical AI company, presented its flagship solution VUNO Med®–DeepCARS® at the 2025 National Teaching Institute & Critical Care…
Route 92 Medical announces results of the SUMMIT MAX randomized clinical trial and receipt of a 510(k) clearance for the HiPoint 88 Reperfusion System.
NEW YORK–(BUSINESS WIRE)–AccurKardia, an innovator in ECG-based diagnostics technology, today announced that its AccurECGTM software platform has been selected as winner of the “Best New Technology Solution for ECG” award in the 9th annual MedTech Breakthrough Awards. The program is conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, […]
Southlake, TX, May 01, 2025 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that it has launched the MyoVista InsightsTM platform and related early adopter program for select reference sites.
This milestone partnership supports the mission of both organizations to improve clinical trials through advanced medical technology. SCHAUMBURG, Ill., April 28, 2025 /PRNewswire/ — HeartcoR Solutions, a leading ECG core lab that conducts cardiac safety studies for the pharmaceutical,…
NEW HOPE, Pa., April 23, 2025 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an industry-sponsored satellite symposium at the Heart Rhythm Society (“HRS”) 2025 Annual Meeting, taking place April 24–27, 2025, in San Diego, California featuring recent advancements in the Company’s atrioventricular interval modulation (“AVIM”) therapy program. The April 25th, 6:45 am PT symposium titled “The Future of Cardiac Pacing: Unlocking the Potential of Atrioventricular Interval Modulation (AVIM) Therapy” will convene leading electrophysiologists, hypertension and heart failure specialists to discuss the unmet need in hypertension, AVIM therapy mechanism of action, and growing body of clinical evidence supporting this novel therapy for the treatment of patients with uncontrolled hypertension who have increased cardiovascular risk with or without an indication for a pacemaker.
COPENHAGEN, Denmark, April 21, 2025 /PRNewswire/ — CathVision, a leader in advanced cardiac electrophysiology (EP) technology, is pleased to announce its participation and exhibition at the Heart Rhythm Society (HRS) 2025 Annual Scientific Sessions at the San Diego Convention Center in…
Real-Time, 360-Degree Imaging Enhances Precision and Confidence in Cardiac Procedures DUBLIN, April 16, 2025 /PRNewswire/ — LUMA Vision Ltd., an innovative leader in advanced cardiac imaging and navigation, today announced the FDA clearance of its VERAFEYE™ Visualization Platform. This…
